Warning letter
Carrington Laboratories Inc.: warning letter of May 11, 2001
FDA warning letter UCM069659 · Dallas District Office
Key facts
| Reference number | UCM069659 |
|---|---|
| Company | Carrington Laboratories Inc. |
| Subject | Current Good Manufacturing Practices for Finished Pharmaceuticals/Adulterated |
| Issue date | May 11, 2001 |
| Posted date | May 11, 2001 |
| Issuing office | Dallas District Office |
| Product type | Drugs |
| CFR sections cited | 21, 211.67, 211.115, 211.137, 211.165, 211.166, 211.180, 211.68(a), 211.100(b), 211.110(a), 211.1, 211.165(e) |
| Country | 3 |
| Inspection city | Irving |
| Inspection ZIP | 75038-4404 |
| Inspection start date | Apr 16, 2001 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: